Candriam S.C.A. Sells 16,510 Shares of Mirum Pharmaceuticals, Inc. $MIRM

Candriam S.C.A. decreased its holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 4.4% during the third quarter, HoldingsChannel.com reports. The firm owned 359,633 shares of the company’s stock after selling 16,510 shares during the quarter. Candriam S.C.A.’s holdings in Mirum Pharmaceuticals were worth $30,854,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. ABS Investment Management LLC purchased a new stake in shares of Mirum Pharmaceuticals during the second quarter valued at $245,847,000. Integrated Wealth Concepts LLC bought a new position in shares of Mirum Pharmaceuticals in the second quarter worth about $27,000. Quantbot Technologies LP bought a new position in shares of Mirum Pharmaceuticals in the second quarter worth about $44,000. State of Wyoming bought a new position in shares of Mirum Pharmaceuticals in the second quarter worth about $52,000. Finally, Fifth Third Bancorp purchased a new position in Mirum Pharmaceuticals in the 1st quarter worth about $56,000.

Trending Headlines about Mirum Pharmaceuticals

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright maintained its “Buy” rating and $202 price target, while still projecting a path to higher earnings over the longer term; its FY2030 EPS estimate rose to $10.76 from $10.03. HC Wainwright estimates
• Positive Sentiment: Mirum’s latest quarter showed revenue up 39.6% year over year to $185.72 million, ahead of analyst expectations. The stock also moved above its 50-day moving average after the earnings release, a potentially supportive technical signal. Stock crosses 50-day moving average
• Neutral Sentiment: Leerink Partners lowered its price target to $140 from $154 but kept an “Outperform” rating. That reflects reduced upside expectations while retaining a positive view of the shares. Leerink Partners rating
• Negative Sentiment: HC Wainwright substantially cut EPS estimates for 2026 and 2027, shifting its FY2027 forecast from a $1.16 profit to a $1.28 loss. It also reduced its FY2028 estimate from $5.38 to $2.64 and FY2029 from $7.21 to $6.85, indicating weaker expected earnings in the coming years despite the maintained Buy rating. HC Wainwright revised EPS estimates
• Negative Sentiment: Quarterly EPS was a loss of $0.87, wider than the expected $0.49 loss. The earnings shortfall tempers the revenue beat and may weigh on investor sentiment. Earnings and stock outlook
• Negative Sentiment: CEO Christopher Peetz sold 20,000 shares worth $1.8 million. The sale was made under a pre-arranged Rule 10b5-1 trading plan, which may soften its significance but can still draw investor attention. CEO share sale

Insider Activity at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, CFO Eric Bjerkholt sold 6,001 shares of the stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $99.90, for a total transaction of $599,499.90. Following the transaction, the chief financial officer directly owned 36,355 shares in the company, valued at $3,631,864.50. This represents a 14.17% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Jolanda Howe sold 658 shares of the stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $100.00, for a total transaction of $65,800.00. Following the transaction, the senior vice president owned 616 shares in the company, valued at approximately $61,600. The trade was a 51.65% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 96,659 shares of company stock worth $9,425,700 over the last three months. 8.32% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

MIRM has been the subject of a number of research analyst reports. Royal Bank Of Canada reiterated an “outperform” rating and set a $155.00 price objective on shares of Mirum Pharmaceuticals in a report on Wednesday, November 4th. UBS Group set a $137.00 price objective on shares of Mirum Pharmaceuticals in a research report on Thursday, August 27th. Raymond James Financial restated a “strong-buy” rating and issued a $189.00 target price on shares of Mirum Pharmaceuticals in a research note on Wednesday. Stifel Nicolaus raised their target price on shares of Mirum Pharmaceuticals from $136.00 to $156.00 and gave the stock a “buy” rating in a research report on Wednesday, October 14th. Finally, TD Cowen raised their target price on shares of Mirum Pharmaceuticals from $140.00 to $145.00 and gave the stock a “buy” rating in a research report on Wednesday, October 21st. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $154.94.

Mirum Pharmaceuticals Stock Performance

Shares of NASDAQ MIRM opened at $93.72 on Monday. Mirum Pharmaceuticals, Inc. has a twelve month low of $63.23 and a twelve month high of $130.00. The firm has a market cap of $6.12 billion, a PE ratio of -6.06 and a beta of 0.75. The business has a fifty day simple moving average of $89.29 and a two-hundred day simple moving average of $98.46. The company has a quick ratio of 1.98, a current ratio of 2.07 and a debt-to-equity ratio of 1.28.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its quarterly earnings results on Tuesday, November 3rd. The company reported ($0.87) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.38). Mirum Pharmaceuticals had a negative return on equity of 97.25% and a negative net margin of 134.75%. The firm had revenue of $185.72 million for the quarter, compared to the consensus estimate of $178.07 million. During the same period in the previous year, the company posted $0.05 EPS. Mirum Pharmaceuticals’s quarterly revenue was up 39.6% compared to the same quarter last year. Analysts expect that Mirum Pharmaceuticals, Inc. will post -1.47 earnings per share for the current fiscal year.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for rare liver and other serious diseases. Founded in 2018, the company works on therapies for conditions with limited treatment options.

Its commercial products include Livmarli (maralixibat), an oral treatment for cholestatic pruritus associated with Alagille syndrome and, in the United States, progressive familial intrahepatic cholestasis. Mirum also markets Cholbam (cholic acid) for certain bile acid synthesis disorders and Chenodal (chenodiol) for cerebrotendinous xanthomatosis.

Mirum serves patients in the United States and other markets, including parts of Europe.